Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jan 22;3(1):e200116.
doi: 10.1148/rycan.2021200116. eCollection 2021 Jan.

Upgrade Rate of Pure Flat Epithelial Atypia Diagnosed at Core Needle Biopsy: A Systematic Review and Meta-Analysis

Rifat A Wahab  1 , Su-Ju Lee  1 , Margaret E Mulligan  1 , Bin Zhang  1 , Mary C Mahoney  1
Affiliations
Meta-Analysis

Upgrade Rate of Pure Flat Epithelial Atypia Diagnosed at Core Needle Biopsy: A Systematic Review and Meta-Analysis

Rifat A Wahab et al. Radiol Imaging Cancer. .

Abstract

Purpose: To perform a systematic review and meta-analysis to calculate the pooled upgrade rate of pure flat epithelial atypia (FEA) diagnosed at core needle biopsy (CNB).

Materials and methods: A PubMed and Embase database search was performed in December 2019. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Study quality and publication bias were assessed. The upgrade rate of pure FEA to cancer, invasive carcinoma, and ductal carcinoma in situ (DCIS), as well as the co-occurrence rate of atypical ductal hyperplasia (ADH), with 95% CIs were calculated. A random effect model was used to integrate the proportions and their corresponding 95% CI. Study heterogeneity was calculated using τ2 and I 2 .

Results: A total of 2482 cases of pure FEA across 42 studies (mean age range, 46-59 years) met inclusion criteria to be analyzed. Significant study heterogeneity was identified (τ2 = 0.001, I 2 = 67%). The pooled upgrade rates reported for pure FEA were 5% (95% CI: 3%, 6%) for breast cancer, 1% (95% CI: 0%, 2%) for invasive carcinoma, and 2% (95% CI: 1%, 3%) for DCIS. When more than 90% of calcifications were removed at CNB, the pooled upgrade rate was 0% (95% CI: 0%, 2%). The pooled co-occurrence rate of ADH at surgical excision was 17% (95% CI: 12%, 21%). Study quality was medium to high with a risk of publication bias (P < .01).

Conclusion: Pure FEA diagnosed at CNB should be surgically excised due to the pooled upgrade rate of 5% for breast cancer. If more than 90% of the targeted calcifications are removed by CNB for pure FEA, close imaging follow-up is recommended.Keywords: Biopsy/Needle Aspiration, Breast, MammographySupplemental material is available for this article.© RSNA, 2021.

PubMed Disclaimer

Conflict of interest statement

Disclosures of Conflicts of Interest: R.A.W. disclosed no relevant relationships. S.J.L. disclosed no relevant relationships. M.EM. disclosed no relevant relationships. B.Z. disclosed no relevant relationships. M.C.M. Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: author is board member of the Radiological Society of North America and the American College of Radiology (ACR); author’s institution received Innovation Grant from ACR; author received royalties from Elsevier for breast textbook; author is editorial board member of Contemporary Diagnostic Radiology. Other relationships: disclosed no relevant relationships.

Figures

Flow diagram of study selection. Of the 307 initially retrieved articles, 176 were excluded as they did not meet the inclusion criteria, and 42 were included the final analysis.
Figure 1:
Flow diagram of study selection. Of the 307 initially retrieved articles, 176 were excluded as they did not meet the inclusion criteria, and 42 were included the final analysis.
Forest plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, and (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy. (a) Pooled upgrade rate to breast cancer by random-effects model (shown in last row) was 5% (95% CI: 3%, 6%). (b) Pooled upgrade rate to invasive breast cancer by random-effects model (shown in last row) was 1% (95% CI: 0%, 2%). (c) Pooled upgrade rate to ductal carcinoma in situ by random-effects model (shown in last row) was 2% (95% CI: 2%, 3%).
Figure 2a:
Forest plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, and (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy. (a) Pooled upgrade rate to breast cancer by random-effects model (shown in last row) was 5% (95% CI: 3%, 6%). (b) Pooled upgrade rate to invasive breast cancer by random-effects model (shown in last row) was 1% (95% CI: 0%, 2%). (c) Pooled upgrade rate to ductal carcinoma in situ by random-effects model (shown in last row) was 2% (95% CI: 2%, 3%).
Forest plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, and (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy. (a) Pooled upgrade rate to breast cancer by random-effects model (shown in last row) was 5% (95% CI: 3%, 6%). (b) Pooled upgrade rate to invasive breast cancer by random-effects model (shown in last row) was 1% (95% CI: 0%, 2%). (c) Pooled upgrade rate to ductal carcinoma in situ by random-effects model (shown in last row) was 2% (95% CI: 2%, 3%).
Figure 2b:
Forest plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, and (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy. (a) Pooled upgrade rate to breast cancer by random-effects model (shown in last row) was 5% (95% CI: 3%, 6%). (b) Pooled upgrade rate to invasive breast cancer by random-effects model (shown in last row) was 1% (95% CI: 0%, 2%). (c) Pooled upgrade rate to ductal carcinoma in situ by random-effects model (shown in last row) was 2% (95% CI: 2%, 3%).
Forest plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, and (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy. (a) Pooled upgrade rate to breast cancer by random-effects model (shown in last row) was 5% (95% CI: 3%, 6%). (b) Pooled upgrade rate to invasive breast cancer by random-effects model (shown in last row) was 1% (95% CI: 0%, 2%). (c) Pooled upgrade rate to ductal carcinoma in situ by random-effects model (shown in last row) was 2% (95% CI: 2%, 3%).
Figure 2c:
Forest plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, and (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy. (a) Pooled upgrade rate to breast cancer by random-effects model (shown in last row) was 5% (95% CI: 3%, 6%). (b) Pooled upgrade rate to invasive breast cancer by random-effects model (shown in last row) was 1% (95% CI: 0%, 2%). (c) Pooled upgrade rate to ductal carcinoma in situ by random-effects model (shown in last row) was 2% (95% CI: 2%, 3%).
Forest plot of the overall upgrade rate to breast cancer at surgical excision when more than 90% of the targeted calcifications were removed at core needle biopsy with a diagnosis of pure flat epithelial atypia. Pooled upgrade rate by random-effects model (shown in last row) was 0% (95% CI: 0%, 2%).
Figure 3:
Forest plot of the overall upgrade rate to breast cancer at surgical excision when more than 90% of the targeted calcifications were removed at core needle biopsy with a diagnosis of pure flat epithelial atypia. Pooled upgrade rate by random-effects model (shown in last row) was 0% (95% CI: 0%, 2%).
Cumulative meta-analysis plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy, and (d) overall upgrade rate to breast cancer at surgical excision when more than 90% of the targeted calcifications were removed at core needle biopsy.
Figure 4a:
Cumulative meta-analysis plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy, and (d) overall upgrade rate to breast cancer at surgical excision when more than 90% of the targeted calcifications were removed at core needle biopsy.
Cumulative meta-analysis plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy, and (d) overall upgrade rate to breast cancer at surgical excision when more than 90% of the targeted calcifications were removed at core needle biopsy.
Figure 4b:
Cumulative meta-analysis plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy, and (d) overall upgrade rate to breast cancer at surgical excision when more than 90% of the targeted calcifications were removed at core needle biopsy.
Cumulative meta-analysis plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy, and (d) overall upgrade rate to breast cancer at surgical excision when more than 90% of the targeted calcifications were removed at core needle biopsy.
Figure 4c:
Cumulative meta-analysis plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy, and (d) overall upgrade rate to breast cancer at surgical excision when more than 90% of the targeted calcifications were removed at core needle biopsy.
Cumulative meta-analysis plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy, and (d) overall upgrade rate to breast cancer at surgical excision when more than 90% of the targeted calcifications were removed at core needle biopsy.
Figure 4d:
Cumulative meta-analysis plots of the (a) overall upgrade rate to breast cancer, (b) upgrade rate to invasive breast cancer, (c) upgrade rate to ductal carcinoma in situ at surgical excision after pure flat epithelial atypia was diagnosed at core needle biopsy, and (d) overall upgrade rate to breast cancer at surgical excision when more than 90% of the targeted calcifications were removed at core needle biopsy.
Funnel plot demonstrates asymmetry, indicating a publication bias (P < .01, Egger test). Each study is represented with a dot; x axis represents total number of pure flat epithelial atypia cases.
Figure 5:
Funnel plot demonstrates asymmetry, indicating a publication bias (P < .01, Egger test). Each study is represented with a dot; x axis represents total number of pure flat epithelial atypia cases.
See this image and copyright information in PMC

References

    1. Sinn HP, Kreipe H. A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care (Basel) 2013;8(2):149–154. - PMC - PubMed
    1. Grabenstetter A, Brennan S, Salagean ED, Morrow M, Brogi E. Flat Epithelial Atypia in Breast Core Needle Biopsies With Radiologic-Pathologic Concordance: Is Excision Necessary? Am J Surg Pathol 2020;44(2):182–190.
    1. Rudin AV, Hoskin TL, Fahy A, et al. Flat Epithelial Atypia on Core Biopsy and Upgrade to Cancer: a Systematic Review and Meta-Analysis. Ann Surg Oncol 2017;24(12):3549–3558. - PubMed
    1. Acott AA, Mancino AT. Flat epithelial atypia on core needle biopsy, must we surgically excise? Am J Surg 2016;212(6):1211–1213. - PubMed
    1. Becker AK, Gordon PB, Harrison DA, et al. Flat ductal intraepithelial neoplasia 1A diagnosed at stereotactic core needle biopsy: is excisional biopsy indicated? AJR Am J Roentgenol 2013;200(3):682–688. - PubMed

LinkOut - more resources